Trastuzumab + capecitabine + cisplatin (TOGA / KEYNOTE-811)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-TRASTUZUMAB` `DRUG-CAPECITABINE` `DRUG-CISPLATIN`

ID	`REG-TRASTUZUMAB-CHEMO-TOGA`
Type	Regimen
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-GASTRIC-2024` `SRC-NCCN-GASTRIC-2025`

Notes

TOGA trial 2010 — first targeted therapy approval in metastatic gastric. mOS 13.8 vs 11.1 chemo-only; HER2 IHC 3+ subgroup mOS 17.9. KEYNOTE-811 added pembrolizumab to trastuzumab+chemo for HER2+ + PD-L1 CPS ≥1 — improved ORR + PFS. T-DXd (trastuzumab-deruxtecan) preferred 2L+ for HER2+ post-trastuzumab failure (DESTINY-Gastric01).

Used By

Indication

IND-ESOPH-METASTATIC-1L-HER2-TRASTUZUMAB-CHEMO - IND-ESOPH-METASTATIC-1L-HER2-TRASTUZUMAB-CHEMO
IND-GASTRIC-METASTATIC-1L-HER2-TOGA - IND-GASTRIC-METASTATIC-1L-HER2-TOGA